All Stories

  1. Global perspectives on MASCC clinical practice guidelines: awareness, implementation and insights to inform future updates
  2. NCX2 Targeting as a Neuroprotective Strategy Against Oxaliplatin-Induced Peripheral Neurotoxicity
  3. Embedding virtual tools and innovative approaches in neuroanatomy teachings: A single center pilot and feasibility experience
  4. Thymoquinone Is Effective in Painful Paclitaxel-Induced Peripheral Neuropathy Without Compromising Anticancer Activity
  5. Shared and specific molecular mechanisms of proteasome inhibitors in chemotherapy‐induced peripheral neurotoxicity
  6. Serum neurofilament light chain (sNFL) as a predictive biomarker for Chemotherapy-induced peripheral neurotoxicity (CIPN): consideration of current evidence, validation steps, and barriers to CIPN biomarker implementation in clinical practice—a narrati...
  7. Interleukin-6 as a keystone cytokine in experimental rat models of chemotherapy-induced peripheral neurotoxicity
  8. The promise of serum neurofilament light as a future primary outcome target in clinical trials testing oxaliplatin-induced peripheral neurotoxicity interventions
  9. Molecular Characterization of Oxaliplatin‐Induced Peripheral Neurotoxicity: The Complex Spectrum of Painful Manifestations
  10. Peripheral Nerve Society Training Grant Program: An Exciting Opportunity Not to Be Missed
  11. Sodium channel modulation as a therapeutic strategy for chemotherapy-induced peripheral neurotoxicity
  12. Special Issue “Mechanisms of Neurotoxicity”
  13. ITF6475, a New Histone Deacetylase 6 Inhibitor, Prevents Painful Neuropathy Induced by Paclitaxel
  14. Patient-reported strategies for prevention and treatment of chemotherapy-induced peripheral neuropathy
  15. 3D Digital tools in neuro-anatomy teaching: from peer-to-peer tutoring to clinically oriented approaches
  16. Paclitaxel alters the microvascular network in the central and peripheral nervous system of rats with chemotherapy‐induced painful peripheral neuropathy
  17. Supportive care 2030 movement: towards unifying ambitions for global excellence in supportive cancer care—an international Delphi study
  18. Repurposing chemotherapy‐induced peripheral neuropathy grading
  19. In vitro neurotoxicity testing: lessons from chemotherapy-induced peripheral neurotoxicity
  20. Molsidomine provides neuroprotection against vincristine-induced peripheral neurotoxicity through soluble guanylyl cyclase activation
  21. Ion Channel and Transporter Involvement in Chemotherapy-Induced Peripheral Neurotoxicity
  22. Translation of paclitaxel-induced peripheral neurotoxicity from mice to patients: the importance of model selection
  23. Abstract
  24. Considerations for establishing and maintaining international research collaboration: the example of chemotherapy-induced peripheral neurotoxicity (CIPN)—a white paper
  25. Patient perceptions of altering chemotherapy treatment due to peripheral neuropathy
  26. Effect of age on metabolomic changes in a model of paclitaxel‐induced peripheral neurotoxicity
  27. Morphofunctional characterisation of axonal damage in different rat models of chemotherapy‐induced peripheral neurotoxicity: the role of nerve excitability testing
  28. Gait analysis in chemotherapy-induced peripheral neurotoxicity rodent models
  29. PNS Abstracts 2023
  30. Toxic medications in Charcot–Marie–Tooth patients: A systematic review
  31. Abstracts
  32. Framework to leverage physical therapists for the assessment and treatment of chemotherapy-induced peripheral neurotoxicity (CIPN)
  33. Axonal degeneration in chemotherapy-induced peripheral neurotoxicity: clinical and experimental evidence
  34. Inhibition of NHE1 transport activity and gene transcription in DRG neurons in oxaliplatin-induced painful peripheral neurotoxicity
  35. Paclitaxel, but Not Cisplatin, Affects Satellite Glial Cells in Dorsal Root Ganglia of Rats with Chemotherapy-Induced Peripheral Neurotoxicity
  36. Morpho-Functional Characterisation of the Rat Ventral Caudal Nerve in a Model of Axonal Peripheral Neuropathy
  37. Neurological Complications of Conventional and Novel Anticancer Treatments
  38. Sodium-Calcium Exchanger 2: A Pivotal Role in Oxaliplatin Induced Peripheral Neurotoxicity and Axonal Damage?
  39. Neurons: The Interplay between Cytoskeleton, Ion Channels/Transporters and Mitochondria
  40. Prospectively assessing serum neurofilament light chain levels as a biomarker of paclitaxel‐induced peripheral neurotoxicity in breast cancer patients
  41. Systems Pharmacology Modeling Identifies a Novel Treatment Strategy for Bortezomib-Induced Neuropathic Pain
  42. Management of Side Effects in the Personalized Medicine Era: Chemotherapy-Induced Peripheral Neurotoxicity
  43. Optimal outcome measures for assessing exercise and rehabilitation approaches in chemotherapy-induced peripheral-neurotoxicity: Systematic review and consensus expert opinion
  44. Rehabilitation, exercise, and related non-pharmacological interventions for chemotherapy-induced peripheral neurotoxicity: systematic review and evidence-based recommendations
  45. Proceedings of the 31st National Conference of the Italian Group for the Study of Neuromorphology “Gruppo Italiano per lo Studio della Neuromorfologia” G.I.S.N., Milan, November 26-27, 2021
  46. Neurology of COVID-19
  47. Chapter 16. Impact of COVID-19 on pre-existing neurological diseases
  48. Translating morphology from bench side to bed side via neurophysiology: 8-min protocol for peripheral neuropathy research
  49. Correction for Pero et al., Pathogenic role of delta 2 tubulin in bortezomib-induced peripheral neuropathy
  50. Abstracts of the Eleventh Annual Meeting of the Associazione Italiana Sistema Nervoso Periferico (ASNP)
  51. Prospective Evaluation of Health Care Provider and Patient Assessments in Chemotherapy-Induced Peripheral Neurotoxicity
  52. Chemotherapy induced peripheral neurotoxicity: Six essential articles for effective future research
  53. Addressing the Need of a Translational Approach in Peripheral Neuropathy Research: Morphology Meets Function
  54. Human Intravenous Immunoglobulin Alleviates Neuropathic Symptoms in a Rat Model of Paclitaxel-Induced Peripheral Neurotoxicity
  55. Pathogenic role of delta 2 tubulin in bortezomib-induced peripheral neuropathy
  56. Prevention of Chemotherapy-Induced Peripheral Neuropathy (CIPN): Current Clinical Data and Future Directions
  57. Characteristics and patterns of pediatric chemotherapy-induced peripheral neuropathy: A systematic review
  58. A review of novel biomarkers and imaging techniques for assessing the severity of chemotherapy-induced peripheral neuropathy
  59. Neuronal uptake transporters contribute to oxaliplatin neurotoxicity in mice
  60. Role of neurophysiology in Chemotherapy-Induced Peripheral Neuropathy (CIPN)
  61. Approaches to measure paediatric chemotherapy-induced peripheral neurotoxicity: a systematic review
  62. Guillain-Barré syndrome related to COVID-19 infection
  63. Neurofilament light chain: a specific serum biomarker of axonal damage severity in rat models of Chemotherapy-Induced Peripheral Neurotoxicity
  64. Differential Contribution of Neuronal Uptake Transporters to Oxaliplatin Peripheral Neurotoxicity
  65. Methods for in vivo studies in rodents of chemotherapy induced peripheral neuropathy
  66. Topiramate prevents oxaliplatin-related axonal hyperexcitability and oxaliplatin induced peripheral neurotoxicity.
  67. Bortezomib and other proteosome inhibitors—induced peripheral neurotoxicity: From pathogenesis to treatment
  68. Chemotherapy‐induced peripheral neurotoxicity: A multifaceted, still unsolved issue
  69. Overview and critical revision of clinical assessment tools in chemotherapy‐induced peripheral neurotoxicity
  70. Taxane and epothilone‐induced peripheral neurotoxicity: From pathogenesis to treatment
  71. Vinca alkaloids, thalidomide and eribulin‐induced peripheral neurotoxicity: From pathogenesis to treatment
  72. Liability Of The Voltage‐Gated Potassium Channel KCNN3 Repeat Polymorphism To Acute Oxaliplatin‐Induced Peripheral Neurotoxicity
  73. Pathogenic Role of Delta 2 Tubulin in Bortezomib Induced Peripheral Neuropathy
  74. Toxic neuropathies
  75. Neurophysiological, nerve imaging and other techniques to assess chemotherapy-induced peripheral neurotoxicity in the clinical and research settings
  76. Introduction to the Italian section for young neurologists
  77. Platinum-drugs induced peripheral neurotoxicity: clinical course and preclinical evidence
  78. Patients’ and physicians’ interpretation of chemotherapy-induced peripheral neurotoxicity
  79. Ghrelin agonist HM01 attenuates chemotherapy-induced neurotoxicity in rodent models
  80. High-dose intravenous immunoglobulins reduce nerve macrophage infiltration and the severity of bortezomib-induced peripheral neurotoxicity in rats
  81. Understanding the quality of life (QOL) issues in survivors of cancer: towards the development of an EORTC QOL cancer survivorship questionnaire
  82. Neurofilament light chain as disease biomarker in a rodent model of chemotherapy induced peripheral neuropathy
  83. Psychometric Testing of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire–Chemotherapy-Induced Peripheral Neuropathy 20-Item Scale Using Pooled Chemotherapy-Induced Peripheral Neuropathy Outcome Measures Stand...
  84. Risk stratification of oxaliplatin induced peripheral neurotoxicity applying electrophysiological testing of dorsal sural nerve
  85. Evaluation of the Profile and Mechanism of Neurotoxicity of Water-Soluble [Cu(P)4]PF6 and [Au(P)4]PF6 (P = thp or PTA) Anticancer Complexes
  86. OATP1B2 deficiency protects against paclitaxel-induced neurotoxicity
  87. Peripheral neuropathy induced by microtubule-targeted chemotherapies: insights into acute injury and long-term recovery
  88. Efficacy of a Novel Sigma-1 Receptor Antagonist for Oxaliplatin-Induced Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Clinical Trial
  89. The Content Validity of a Chemotherapy-Induced Peripheral Neuropathy Patient-Reported Outcome Measure
  90. Erratum to: Distal pain and carpal tunnel syndrome diagnosis among cashiers: a longitudinal study
  91. Distal pain and carpal tunnel syndrome diagnosis among cashiers: a longitudinal study
  92. Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20)
  93. Abstracts
  94. Chemotherapy-induced peripheral neurotoxicity – outcome measures: the issue
  95. Severe, reversible nelarabine-induced neuropathy and myelopathy
  96. Abstracts
  97. Early ficolin-1 is a sensitive prognostic marker for functional outcome in ischemic stroke
  98. Genetic determinants of chronic oxaliplatin-induced peripheral neurotoxicity: a genome-wide study replication and meta-analysis
  99. Chemotherapy-Induced Peripheral Neurotoxicity in Cancer Survivors: An Underdiagnosed Clinical Entity?
  100. Long-term course of oxaliplatin-induced polyneuropathy: a prospective 2-year follow-up study
  101. Correspondence between neurophysiological and clinical measurements of chemotherapy-induced peripheral neuropathy: secondary analysis of data from the CI-PeriNomS study
  102. Management of Side Effects in the Personalized Medicine Era: Chemotherapy-Induced Peripheral Neuropathy
  103. Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin
  104. Neuropathic pain and chemotherapy-induced peripheral neurotoxicity: the issue
  105. Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS)
  106. Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: Results from a prospective multicenter study
  107. Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients
  108. Neuroprotectant agents against oxaliplatin induced neurotoxicity: lackings, facts and future prospective
  109. Advanced age and liability to oxaliplatin-induced peripheral neuropathy:post hocanalysis of a prospective study
  110. Incidence of atypical acute nerve hyperexcitability symptoms in oxaliplatin-treated patients with colorectal cancer
  111. Neurophysiological examination of dorsal sural nerve
  112. The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings
  113. Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients
  114. Clinical pattern and associations of oxaliplatin acute neurotoxicity
  115. Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics
  116. Chemotherapy-induced peripheral neurotoxicity can be misdiagnosed by the National Cancer Institute Common Toxicity scale
  117. Chemotherapy-Induced Neuropathy
  118. Chemotherapy-Induced Peripheral Neurotoxicity assessment: A critical revision of the currently available tools